Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aviron -- Ignore unavailable to you. Want to Upgrade?

To: Gerald Walls who wrote (491)	7/14/1999 2:57:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 645

pharmacology.miningco.com This could be exerting some effect on AVIR party. Also the Convertibles at $35, makes this a kind of a ceiling (my speculation, I do not fully understand this convertible business). Since Relenza will be out sooner (if FDA approved) and FluMist is taken longer than expected. There were four "bridging" studies (some ongoing?): 1. Children with asthma, 2. General population children (school settings, 3 years duration?) 3. Adults (just published) 4. Seniors (combined regular IM, with nasal, due to poor IM response). All by recollections please confirm your facts.